

PRIOR AUTHORIZATION REQUEST FORM **EOC ID:**

Gleostine (Iomustine)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

	Prescriber Name:			
Patient Name:	Supervising Physician:			
Member/Subscriber Number:	Fax:	Phone:		
Date of Birth:	Office Contact:	. Hone.		
Group Number:	NPI:	State Lic ID:		
Address:	Address:			
City, State ZIP:	City, State ZIP:			
Primary Phone:	Specialty/facility name	(if applicable):		
Drug Name and Strength:				
Directions / SIG:				
Please attach any pertinent medical history or information following qu	n for this patient that ma	ay support approval. Please answer the		
Q1. What diagnosis is this drug being prescribed for?				
☐ Hodgkin's lymphoma				
☐ Primary or metastatic brain tumor☐ Other				
Other				
Q2. If you selected "other" in question 2, please provide NCCN compendia or guidelines.	documentation that us	se is consistent with a category 1 per		
Q3. Please provide ICD code(s) for diagnosis				
Q4. Is the prescribing physician an Oncologist or Hematol	ogist?			
☐ Yes	☐ No			
Q5. If for brain tumors, is Gleostine being used following a	ppropriate surgical and	d/or radiotherapeutic procedures?		
☐ Yes	☐ No			
Q6. If for Hodgkin's lymphoma, did the patient have diseas	se progression followin	g initial chemotherapy?		



PRIOR AUTHORIZATION REQUEST FORM EOC ID: Gleostine (lomustine)

Phone: 800-728-7947 Fax back to: 866-880-4532

The Scott & White Health Plan Pharmacy Department manages the pharmacy drug benefit for your patient. Certain requests for coverage require review with the prescribing physician. Please answer the following questions and fax this form to the number listed above. Please note any information left blank or illegible may delay the review process.

plank or illegible may delay the review process.		
Patient Name:	Prescriber Name: Supervising Physician:	
☐ Yes	□ No	
Q7. If for Hodgkin's lymphoma, will the	e patient be using Gleostine as part of combination chemotherapy?	,
☐ Yes	□ No	
Q8. Additional Comments		
Prescriber Signature	e Date	
	box and signing above, I certify that applying the standard review ting the enrollee or the enrollee's ability to regain maximum function	meframe may
	result in a medical necessity denial. Requesting providers may speak to a dring the case to have an opportunity to help impact the decision on a requ	

This telecopy transmission contains confidential information belonging to the sender that is legally privileged. This information is intended only for the use of the individual or entity named above. The authorized recipient of this information is prohibited from disclosing this information to any other party. If you are not the intended recipient, you are hereby notified that any disclosure, copying, distribution or action taken in reference to the contents of this document is strictly prohibited. If you have received this telecopy in error, please notify the sender immediately to arrange for the return of this document